Language:

Metformin and COVID-19: From cellular mechanisms to reduced mortality

Diabetes & metabolism, 2020-11, Vol.46 (6), p.423-426 [Peer Reviewed Journal]

2020 Elsevier Masson SAS ;Copyright © 2020 Elsevier Masson SAS. All rights reserved. ;2020 Elsevier Masson SAS. All rights reserved. 2020 Elsevier Masson SAS ;ISSN: 1262-3636 ;ISSN: 1878-1780 ;EISSN: 1878-1780 ;DOI: 10.1016/j.diabet.2020.07.006 ;PMID: 32750451

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Metformin and COVID-19: From cellular mechanisms to reduced mortality
Author: Scheen, A.J.
Subjects: Aged ; Comorbidity ; COVID-19 - epidemiology ; COVID-19 - mortality ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - epidemiology ; Diabetes Mellitus, Type 2 - mortality ; Endocrinologie, métabolisme & nutrition ; Endocrinology, metabolism & nutrition ; Hospitalization ; Human health sciences ; Humans ; Hypoglycemic Agents - therapeutic use ; Immunologie & maladie infectieuse ; Immunology & infectious disease ; Inflammation ; Inflammation - prevention & control ; Male ; Meta-analysis ; Metformin ; Metformin - therapeutic use ; Middle Aged ; Mini Review ; Mortality ; Pharmacie, pharmacologie & toxicologie ; Pharmacy, pharmacology & toxicology ; Prognosis ; SARS-CoV-2 ; Sciences de la santé humaine ; Type 2 diabetes
Is Part Of: Diabetes & metabolism, 2020-11, Vol.46 (6), p.423-426
Description: Type 2 diabetes mellitus (T2DM) is associated with both poorer clinical outcomes during the COVID-19 pandemic and an increased risk of death in such hospitalized patients. While the role of glucose control has been emphasized to improve the prognosis, the impact of different glucose-lowering agents remains largely unknown. Metformin remains the first-line pharmacological choice for the management of hyperglycaemia in T2DM. Because metformin exerts various effects beyond its glucose-lowering action, among which are anti-inflammatory effects, it may be speculated that this biguanide might positively influence the prognosis of patients with T2DM hospitalized for COVID-19. The present concise review summarizes the available data from observational retrospective studies that have shown a reduction in mortality in metformin users compared with non-users, and briefly discusses the potential underlying mechanisms that might perhaps explain this favourable impact. However, given the potential confounders inherently found in observational studies, caution is required before drawing any firm conclusions in the absence of randomized controlled trials.
Publisher: France: Elsevier Masson SAS
Language: English
Identifier: ISSN: 1262-3636
ISSN: 1878-1780
EISSN: 1878-1780
DOI: 10.1016/j.diabet.2020.07.006
PMID: 32750451
Source: MEDLINE
Alma/SFX Local Collection

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Metformin and COVID-19: From cellular mechanisms to reduced mortality

2020 Elsevier Masson SAS ;Copyright © 2020 Elsevier Masson SAS. All rights reserved. ;2020 Elsevier Masson SAS. All rights reserved. 2020 Elsevier Masson SAS ;ISSN: 1262-3636 ;ISSN: 1878-1780 ;EISSN: 1878-1780 ;DOI: 10.1016/j.diabet.2020.07.006 ;PMID: 32750451

Searching Remote Databases, Please Wait